Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 7/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2517317 | 0.85 | GCK (0.70) | GCKNPC1ALDH1A1HPGD | |
| SCHEMBL2511794 | 0.82 | GCK (0.56) | GCKLMNANPC1ALDH1A1 | |
| SCHEMBL2511310 | 0.81 | GCK (0.70) | GCKNPC1ALDH1A1HPGD | |
| SCHEMBL2512763 | 0.80 | GCK (0.60) | GCKTP53NPC1ALDH1A1HPGD | |
| SCHEMBL2517498 | 0.77 | GCK (0.56) | GCKLMNANPC1ALDH1A1HPGD | |
| SCHEMBL2513144 | 0.77 | GCK (0.54) | GCKLMNA | |
| SCHEMBL2516092 | 0.76 | GCK (0.75) | GCKNPC1ALDH1A1HPGD | |
| SCHEMBL2513482 | 0.73 | GCK (0.66) | GCKIDO1 | |
| SCHEMBL2514574 | 0.71 | GCK (0.68) | GCK | |
| SCHEMBL2512504 | 0.71 | GCK (0.68) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034822-B2 | Glucokinase activators | TAKEDA SAN DIEGO, INC. (US) | 2011-10-11 | — | — | US | claimed |
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-09-13 | — | — | US | claimed |
| US-8034822-B2 | Glucokinase activators | TAKEDA SAN DIEGO, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-8034822-B2 | Glucokinase activators | TAKEDA SAN DIEGO, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| EP-2001875-A2 | GLUCOKINASE ACTIVATORS | Takeda San Diego, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007104034-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007104034-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | GCK 1/4885LMNA 3747/4885SSTR5 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.